The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines

• Published in: Asian journal of andrology 2019-09, Vol.21 (5), p.460-467
• Main Authors: Orellana-Serradell, Octavio, Herrera, Daniela, Castellón, Enrique A, Contreras, Héctor R
• Format: Article
• Language: English
• Subjects: Analysis; Androgens; Apoptosis; Breast cancer; Cancer therapies; Care and treatment; Cell lines; Chemical properties; Chemoprevention; Chemotherapy; Development and progression; Drug resistance; Genetic aspects; Genotype & phenotype; Infections; Lymphoma; Original; Patient outcomes; Prostate cancer; Proteins; Transcription factors; Zinc finger proteins
• ISSN: 1008-682X; 1745-7262
• DOI: 10.4103/aja.aja_1_19

One of the factors promoting tumoral progress is the abnormal activation of the epithelial-mesenchymal transition (EMT) program which has been associated with chemoresistance in tumoral cells. The transcription factor zinc finger E-box-binding homeobox 1 (ZEB1), a key EMT activator, has recently been related to docetaxel resistance, the main chemotherapeutic used in advanced prostate cancer treatment. The mechanisms involved in this protective effect are still unclear. In a previous work, we demonstrated that ZEB1 expression induced an EMT-like phenotype in prostate cancer cell lines. In this work, we used prostate cancer cell lines 22Rv1 and DU145 to study the effect of ZEB1 modulation on docetaxel resistance and its possible mechanisms. The results showed that ZEB1 overexpression conferred to 22Rv1 cell resistance to docetaxel while its silencing made DU145 cells more sensitive to it. Analysis of resistance markers showed no presence of ATP-binding cassette subfamily B member 1 (MDR1) and no changes in breast cancer resistance protein (BCRP) or ATP-binding cassette subfamily C member 10 (MRP7). However, a correlation between ZEB1, multidrug resistance-associated protein 1 (MRP1), and ATP-binding cassette subfamily C member 4 (MRP4) expression was observed. MRP4 inhibition, using MK571, resensitized cells with ZEB1 overexpression to docetaxel treatment. In addition, modulation of ZEB1 and subsequent change in MRP4 expression correlated with a lower apoptotic response to docetaxel, characterized by lower B-cell lymphoma 2 (Bcl2), high BCL2-associated X protein (Bax), and high active caspase 3 expression. The response to docetaxel in our model seems to be mediated mainly by activation of the apoptotic death program. Our results showed that modulation of MRP4 could be a mediator of ZEB1-related resistance to docetaxel in prostate cancer, making it a possible marker for chemotherapy response in patients who do not express MDR1.